Raised blood pressure remains the leading modifiable risk factor for cardiovascular disease and premature mortality worldwide ...
When the heart begins to fail, the body does everything in its power to fix the situation. But sometimes, those compensatory mechanisms ultimately do more harm than good. Such is the case with the ...
In a phase 2 trial, an investigational drug that inhibits aldosterone synthase significantly lowered albuminuria in patients with or without type 2 diabetes. PHILADELPHIA—A novel selective aldosterone ...
Lorundrostat, a novel aldosterone synthase inhibitor, reduces blood pressure among patients with uncontrolled hypertension on at least two drugs, according to results from the phase II Target-HTN ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results